The Roundup Settlement Was Just Delayed — and the Supreme Court Just Changed Everything for Your Non-Hodgkin Lymphoma Claim
If you used Roundup and later heard the words “non-Hodgkin lymphoma” from an oncologist, you already know the feeling — the floor drops, and every decision after that is made in a fog. Now you are hearing about a $7.25 billion settlement that was supposed to get a final approval hearing on July 9, and that hearing has been pushed to August 19. And on top of that, the United States Supreme Court just ruled 7-2 that federal pesticide law blocks the very heart of most Roundup cancer lawsuits — the claim that Monsanto should have warned you about cancer on the label.
You probably have two questions right now, and we are going to answer both of them straight: What does the delay mean for me, and does the Supreme Court ruling kill my case? The delay means the judge wants more time to consider objections — it does not kill the settlement, and it does not kill your rights. The Supreme Court ruling is a serious blow to one legal theory — failure to warn — but it does not eliminate every theory, and the fight over what survives is just beginning. We are Attorney911 — The Manginello Law Firm, PLLC, and we handle toxic tort and product liability cases for people whose lives were overturned by a product they were told was safe. This page is not a news recap. It is a translation of what the law just did to your rights, what still survives, and what you should be doing right now to protect yourself — whether you are in the settlement class, whether you opted out, or whether you have not yet been diagnosed but were exposed for years.
What Happened: The Postponement, the Settlement, and the Two-Step Strategy
St. Louis Circuit Court Judge Timothy Boyer postponed the final fairness hearing on Bayer’s proposed $7.25 billion nationwide Roundup class-action settlement from July 9 to August 19, 2026. In a June 23 memorandum, the judge wrote that the postponement would allow the parties to fully brief objections that had already been filed and account for delays caused while the case was temporarily pending in federal court. Bayer agreed with the order — which tells you the company is not panicking about the delay. It is comfortable with more time, because time works in favor of a defendant that has already committed to the dollar amount.
Here is the bigger picture. This settlement is one pillar of a two-step strategy Bayer designed to end the glyphosate liability it inherited when it acquired Monsanto for $63 billion in 2018. Step one: the $7.25 billion nationwide class-action settlement, meant to cover most of the approximately 67,000 claims from people who allege that glyphosate — the active ingredient in Roundup — caused their non-Hodgkin lymphoma. Bayer has already paid about $10 billion to resolve prior glyphosate claims, on top of this proposed settlement. Step two: winning a Supreme Court ruling that federal pesticide law preempts state-law failure-to-warn claims. That is exactly what happened on June 25, 2026, when the Supreme Court ruled 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act — FIFRA — preempts state-law claims seeking cancer warnings on Roundup’s label beyond what the EPA has approved.
The opt-out and objection deadline was June 4. If you did not opt out by that date, you are currently within the settlement class. If you did opt out, you retained your right to pursue an individual lawsuit. And if you have been exposed to Roundup but have not yet been diagnosed with non-Hodgkin lymphoma, your situation is legally the most uncertain of all — because the settlement’s ability to bind future claimants is constitutionally questionable, and we will explain why below.
The $7.25 Billion Settlement Explained: What It Covers, How It Is Structured, and What It Does NOT Cover
The proposed nationwide settlement is a class action — meaning it is designed to bind most of the approximately 67,000 people who have filed claims alleging that glyphosate caused their non-Hodgkin lymphoma, unless they affirmatively opted out by June 4. The $7.25 billion fund, spread across roughly 67,000 claimants, implies a per-claimant average in the low six figures before attorney fees and litigation costs — but that average is misleading, because individual allocations are tiered by a matrix that considers diagnosis severity, exposure duration, age at exposure, and other factors.
Here is what that means in practice. The settlement matrix creates tiers — and the difference between tiers can be dramatic. A claimant with an aggressive NHL subtype, documented heavy long-term exposure (agricultural or landscaping work over many years), and strong causation evidence will land in a higher tier than someone with an indolent subtype, shorter exposure history, and weaker documentation. The per-claimant allocations likely range from approximately $50,000 at the low end to $500,000 or more at the high end, before attorney fees (typically 25-40% in mass tort cases) and litigation costs are deducted. After fees and costs, a lower-tier claimant could receive a net payment that falls below $50,000 — for a cancer diagnosis.
What the settlement does NOT cover is just as important as what it does. The settlement as proposed may not adequately compensate claimants whose individual cases — if tried separately — could be worth $1 million to $5 million or more, particularly where punitive damages are available. Missouri does not impose statutory caps on compensatory or punitive damages in product liability cases, which makes it a uniquely favorable venue for individual verdicts. And the settlement’s attempt to bind people who may develop cancer in the future — people who have been exposed to Roundup but have not yet been diagnosed — is the subject of what Judge Vince Chhabria, the federal judge overseeing the Roundup multidistrict litigation in the Northern District of California, called “grave concerns” about whether a class action can constitutionally bind people who do not yet know they are injured.
That is the tension at the heart of this postponement. The objectors — attorneys representing several individuals diagnosed with NHL who oppose the settlement — tried to move the case to federal court on May 22, hoping it would be transferred to Judge Chhabria’s MDL. U.S. District Judge Henry Autrey ruled June 17 that the opponents lacked authority to remove the case to federal court, sending it back to state court. The objectors have appealed that ruling. Bayer’s subsidiary Monsanto asked Judge Boyer to postpone the hearing to address objections and disputes over opt-out requests following what the company characterized as a “sham removal” of the case to federal court.
The SCOTUS Game-Changer: FIFRA Preemption and What It Means for Your Failure-to-Warn Claim
This is the part that matters most, and we are not going to sugarcoat it. The Supreme Court’s 7-2 ruling on June 25, 2026 — holding that FIFRA preempts state-law failure-to-warn claims seeking cancer warnings on Roundup’s label — is a substantial blow to the primary legal theory that drove the early Roundup verdicts. The failure-to-warn theory was the spine of the cases that produced multi-million-dollar jury verdicts against Monsanto: the argument that the company knew or should have known about the association between glyphosate exposure and non-Hodgkin lymphoma and failed to provide adequate warnings on the product label. That theory is now largely foreclosed for future state-law claims.
Here is why. FIFRA is the federal statute under which the EPA registers pesticide products and approves their labeling. The EPA has historically taken the position that glyphosate is “not likely to be carcinogenic to humans.” The Supreme Court’s ruling means that if the EPA did not require a cancer warning on Roundup’s label, state courts cannot impose a different warning requirement through tort law — because that would effectively override the federal labeling regime. The preemption is express: FIFRA’s text bars states from imposing labeling requirements that are “in addition to or different from” what FIFRA prescribes.
But — and this is critical — the ruling specifically targets failure-to-warn claims based on label content. It does not directly address every product liability theory, and the surviving theories are where the next chapter of Roundup litigation will be fought.
Surviving Legal Theories After the Supreme Court Ruling: What Still Lives
The failure-to-warn theory is gravely wounded, but it is not the only path. Here are the theories that may survive the preemption ruling, each with its own challenges:
Design defect. The theory that Roundup was unreasonably dangerous in its design or formulation — or that a safer alternative formulation was feasible — was not directly addressed by the FIFRA preemption ruling on labeling claims. A design defect claim does not ask for a different label; it asks whether the product itself was dangerously designed. This theory may remain viable for non-settling plaintiffs, subject to the product liability framework of each jurisdiction. The challenge: design defect in the glyphosate context is less tested than failure to warn, and courts will be wrestling with whether FIFRA preemption extends beyond labeling to other strict liability theories.
Negligence beyond labeling. A negligence theory can encompass claims beyond what the label says — such as failure to conduct adequate long-term carcinogenicity studies, manipulation of scientific literature, ghostwriting of studies, or post-market surveillance failures. If the negligence claim is not premised on a duty to warn on the label, it may survive preemption. The challenge: the defense will argue that any negligence theory that would effectively require a different label is preempted just like a direct failure-to-warn claim.
Breach of implied warranty. The theory that Roundup was not fit for its ordinary purpose or was unreasonably dangerous beyond consumer expectations. Viability depends on whether courts extend FIFRA preemption to warranty theories under applicable state law. This is untested ground in the glyphosate context.
The regulatory and scientific record as proof. Even after preemption, the scientific evidence remains what it is. The International Agency for Research on Cancer — IARC — classified glyphosate as a Group 2A “probable human carcinogen” in 2015, a classification that has been central to plaintiff expert causation testimony. The EPA’s position that glyphosate is “not likely to be carcinogenic to humans” creates a tension that the defense will exploit aggressively — but the IARC classification and the epidemiological literature (including studies by De Roos, McDuffie, Eriksson, and others) remain part of the scientific record that supports general causation.
What this means for you: if you are a non-settling plaintiff or a future claimant, your case is not dead — but it is materially harder than it was before June 25, 2026. The value of individual cases has been depressed because the primary theory that drove early multi-million-dollar verdicts is now preempted. The cases that survive will need to be built on design defect, negligence beyond labeling, and warranty theories that are less established in the glyphosate context and face uncertain judicial reception.
The Defendant: Bayer AG and Monsanto Company — The Corporate Structure You Need to Understand
When you hear “Roundup lawsuit,” the defendant is not a single company. It is a layered corporate structure designed, in part, to manage liability. Here is the map:
Bayer AG is the German multinational pharmaceutical and life sciences conglomerate that acquired Monsanto in 2018 for $63 billion, inheriting all of Monsanto’s Roundup and glyphosate liability. Bayer is the architect of the two-step settlement-plus-preemption strategy. Bayer’s Crop Science Division operates from Creve Coeur, Missouri — St. Louis County — which is why the state-court litigation is anchored in St. Louis.
Monsanto Company is the wholly-owned subsidiary of Bayer. Monsanto was the original manufacturer, marketer, and distributor of Roundup herbicide. Monsanto designed the product label and the warning language at issue. Monsanto’s internal corporate documents — emails, memos, research protocols, internal toxicity studies, and alleged ghostwriting arrangements — are the discovery record that drove the punitive damages case in early trials. Those documents, showing what Monsanto knew about glyphosate’s potential carcinogenicity and when it knew it, remain powerful evidence even after the preemption ruling — because they support negligence and design defect theories that survive.
Bayer has taken the position that Roundup is safe to use. The company has said the proposed nationwide settlement would cover most of the 67,000 claims. And the company has already paid approximately $10 billion to resolve prior glyphosate-related NHL claims — a figure that tells you the liability was real enough that Bayer chose to pay rather than fight every case.
The corporate structure matters because it affects who you sue, where you sue, and what insurance or corporate assets stand behind the defendant. Bayer is a deep-pocket defendant with the resources to fund a global settlement — but also the resources to fight individual cases through trial and appeal. Monsanto, as the entity that actually made and sold Roundup, is the primary tort defendant. The relationship between parent and subsidiary, and the question of whether Bayer can be held directly liable for Monsanto’s conduct, are issues that depend on the specific jurisdiction and the specific claims pleaded.
The Medicine: Non-Hodgkin Lymphoma — What It Is, How It Is Treated, and What It Costs
Non-Hodgkin lymphoma is a hematologic cancer — a cancer of the blood — that originates in the lymphatic system, specifically in lymphocytes (white blood cells). NHL is not a single disease; it is a group of more than 70 subtypes that range from indolent (slow-growing) to aggressive (fast-growing), and the subtype you have determines everything about your treatment, your prognosis, and the cost of your care.
Diagnosis and subtyping. NHL is diagnosed through lymph node biopsy, with pathology reports confirming the specific subtype and stage. The pathology report is the foundation document — it names the exact disease, and that diagnosis is the backbone of your damages case. Immunophenotyping and cytogenetic analysis further refine the subtype, which drives treatment decisions.
Treatment regimens. Depending on subtype and stage, treatment may include combination chemotherapy (R-CHOP is a common regimen for diffuse large B-cell lymphoma, the most common aggressive subtype), radiation therapy, immunotherapy (monoclonal antibodies like rituximab), and in some cases stem cell transplantation. Five-year survival rates vary dramatically — from over 70% for some indolent subtypes to under 60% for certain aggressive subtypes, and far lower for relapsed/refractory disease.
What the family observes. NHL does not just appear on a scan one day. The person may have noticed enlarged lymph nodes — a lump in the neck, under the arm, or in the groin. They may have experienced unexplained weight loss, night sweats, fatigue, or recurrent infections. The period between first symptoms and diagnosis can be weeks to months, and that period is part of the story — the delay, the uncertainty, the fear.
The proof problem the defense exploits. NHL is not rare in the general population, and it has many known causes and risk factors unrelated to glyphosate — including age, immune suppression, certain infections, and other chemical exposures. The defense argues that your NHL was idiopathic — meaning it came from nowhere, or from something else. The counter requires dose reconstruction (documenting how much Roundup you used, how often, and for how long), general causation evidence (the IARC classification and the epidemiological literature linking glyphosate to NHL), and specific causation testimony from a board-certified oncologist or hematopathologist who can connect your exposure to your disease.
What it costs. Economic damages include past and future medical treatment costs — which can reach hundreds of thousands of dollars for aggressive subtypes requiring combination chemotherapy, and millions for subtypes requiring stem cell transplantation or novel immunotherapies. Add lost wages and diminished earning capacity, and out-of-pocket costs. Non-economic damages — physical pain and suffering, emotional distress, loss of quality of life, and the psychological toll of a cancer diagnosis and treatment regimen — are real and compensable, particularly in Missouri where there are no statutory caps on these damages in product liability cases. For families who have lost a loved one to NHL, wrongful death claims carry their own set of damages — the financial support the person would have provided, the companionship lost, the life that was taken.
The Evidence Clock: What Exists, Who Holds It, and How Fast It Disappears
Every mass tort case lives or dies on evidence, and the evidence in a Roundup case falls into five categories — each with its own shelf life and its own urgency.
Your medical records. Your NHL diagnosis, pathology reports confirming subtype and stage, treatment history, oncologist records, and prognosis documentation. These establish specific causation — the existence, type, and severity of the cancer. Medical records are generally retained per HIPAA and state record-retention requirements, so they are relatively stable. But delay in obtaining pathology confirmation can complicate causation expert opinions, and treatment records that document the progression of your disease are something your lawyer needs to assemble early.
Your exposure history documentation. This is the evidence that separates a strong case from a weak one. Roundup purchase receipts, product containers with lot numbers, employment records for agricultural, landscaping, or groundskeeping workers, and witness statements regarding the frequency and duration of your Roundup use. These establish the dose-response relationship and the temporal fit between glyphosate exposure and your NHL diagnosis. This evidence is HIGH URGENCY — receipts degrade, containers are discarded, memories fade, and employment records may be destroyed per standard retention schedules. Product identification is a known battleground in mass tort cases, and the person who can say “I bought Roundup at the hardware store every spring for fifteen years and sprayed it every weekend” has a stronger case than the person who says “I think I used it sometimes.”
Internal Monsanto and Bayer corporate documents. Emails, memos, research protocols, internal toxicity studies, ghostwriting arrangements, and regulatory submission drafts. These are the core of the punitive damages case and the knowledge-based liability theories. Much of this evidence has already been secured through prior MDL discovery — but additional state-court-specific discovery may be needed for non-MDL cases. Document retention holds should be issued immediately for any new individual filings.
The regulatory and scientific record. The IARC monograph classifying glyphosate as a Group 2A probable human carcinogen, EPA registration filings, EPA Scientific Advisory Panel transcripts, and the published epidemiological studies. This is the general causation foundation — the scientific literature linking glyphosate exposure to NHL. These are permanent public records, stable and accessible. The evolving EPA re-registration decisions may alter the regulatory landscape, so the current status of EPA’s glyphosate review is something to monitor.
Expert witness reports and Daubert rulings from the MDL. Prior Daubert rulings from Judge Chhabria in the federal Roundup MDL provide a roadmap for the admissibility of causation experts in individual cases. Expert reports establish the analytical framework connecting your exposure to your disease. These are already produced in the MDL and should be obtained and analyzed for any individual case strategy.
The urgency is real. The fastest-dying evidence is your personal exposure documentation — the receipts, the containers, the memory of exactly how much Roundup you used and when. Every month that passes, that evidence gets weaker. If you have not already gathered it, that is the first thing to do.
The Defendant’s Playbook: What Bayer and Monsanto Will Do — and How Each Move Is Countered
Bayer and Monsanto have run a sophisticated, multi-layered litigation strategy. Here are the plays you should expect, and the counter to each:
Play 1: The preemption shield. Bayer will use the Supreme Court’s FIFRA preemption ruling to argue that every state-law claim seeking a cancer warning on the label is barred. The counter: the ruling targets failure-to-warn claims based on label content — it does not directly address design defect, negligence beyond labeling, or warranty theories. The fight over which theories survive is just beginning, and a well-pleaded complaint that avoids label-based warnings and instead targets the product’s design and the company’s conduct (study manipulation, research suppression, post-market surveillance failures) presents a different legal question that the Supreme Court did not decide.
Play 2: The EPA compliance argument. Bayer will argue that because the EPA approved Roundup’s labeling and has taken the position that glyphosate is “not likely to be carcinogenic to humans,” the company was entitled to rely on the federal regulatory regime. The counter: EPA registration is not a finding of safety — it is a registration decision. The IARC, an arm of the World Health Organization, classified glyphosate as a Group 2A probable human carcinogen. The tension between EPA’s position and IARC’s classification is itself evidence that the science was contested, and a company that knew about the IARC classification had a duty to investigate further — even if it did not have a duty to add a warning to the label.
Play 3: The settlement pressure. Bayer will use the $7.25 billion settlement fund and the SCOTUS ruling together to pressure non-settling claimants into accepting settlement allocations that are lower than what their individual cases might be worth. The argument is simple: “The Supreme Court just weakened your case, and the settlement is your best option.” The counter: the settlement matrix values are not individual case values. A person with an aggressive NHL subtype, documented heavy long-term exposure, strong causation experts, and viable design defect and negligence theories may have a case worth materially more than the settlement allocation — even after the preemption ruling. The decision to accept a settlement allocation versus pursuing an individual case is a strategic one that should be made with full information about the surviving legal theories, the strength of your specific evidence, and the venue where an individual case would be filed.
Play 4: The “idiopathic cancer” defense. Bayer’s experts will argue that your NHL was caused by something other than glyphosate — age, genetics, immune suppression, other chemical exposures, or pure bad luck. The counter: dose reconstruction from your exposure history, general causation evidence from the IARC classification and the epidemiological literature, and specific causation testimony from a treating oncologist who can connect your documented exposure to your specific disease. The defense wins this argument when the plaintiff cannot document exposure — which is why the evidence preservation discussion above is not academic. It is the case.
Play 5: The “sham removal” framing and objector marginalization. Bayer has characterized the objectors’ attempt to move the case to federal court as a “sham removal” and has used that framing to paint the objectors as self-interested disruptors who are delaying compensation to 67,000 claimants. The counter: the objectors raised a legitimate constitutional question — whether a class action can bind people who may develop cancer in the future — and Judge Chhabria’s “grave concerns” about that question are not frivolous. The fairness of a settlement is not measured only by how quickly it can be approved, and the postponement gives the court time to consider whether the settlement is fair, reasonable, and adequate — including whether it adequately compensates claimants relative to their individual case values.
Case Value: What a Roundup NHL Claim Is Worth — Honestly Framed
We are not going to give you a number and call it a prediction. We are going to give you the framework that determines the number, and the honest range that the current legal landscape supports.
Settlement-class claims (within the $7.25 billion fund): Per-claimant allocations likely range from approximately $50,000 to $500,000+ depending on the tiering matrix, before attorney fees (typically 25-40%) and costs. A lower-tier claim — less severe NHL subtype, shorter exposure history, weaker causation documentation — might produce a net payment to the claimant of $30,000 to $90,000 after fees. A higher-tier claim — aggressive subtype, documented heavy long-term exposure, strong causation evidence — might produce a net payment of $200,000 to $350,000 or more after fees. These are estimates based on the fund size and claimant count; the actual matrix is the governing document, and individual allocations are determined by the claims administrator.
Individual verdict-track cases (post-SCOTUS): The value of non-settling individual cases has been materially depressed by the FIFRA preemption ruling. Before the ruling, individual Roundup cases with strong facts produced verdicts in the millions — but many of those verdicts were driven by the failure-to-warn theory that is now preempted, and several were reduced on appeal. Post-SCOTUS, an individual case built on surviving theories (design defect, negligence beyond labeling, warranty) faces uncertain judicial reception. The honest range for a strong individual case post-SCOTUS — aggressive NHL subtype, documented heavy long-term exposure, strong causation experts, punitive damages evidence from Monsanto’s internal documents — might be $100,000 to $500,000 at settlement, with trial verdicts potentially higher but facing the headwind of preemption arguments on appeal. Cases with weaker exposure documentation or less aggressive disease subtypes are worth less, and some may not be economically viable to pursue individually.
Punitive damages. Missouri does not impose statutory caps on punitive damages in product liability cases. Missouri punitive damages require a showing of outrageous conduct or conscious disregard for consumer safety — a standard that plaintiffs have historically argued Monsanto’s conduct meets, based on allegations of scientific literature manipulation, study ghostwriting, and suppression of internal evidence of glyphosate’s carcinogenic potential. If those allegations can be proven through the internal corporate documents secured in MDL discovery, punitive damages remain a live theory — even after the preemption ruling — because they go to the company’s conduct, not to the label.
The Supreme Court’s 7-2 ruling held that FIFRA preempts state-law failure-to-warn claims that would require cancer warnings on Roundup’s label beyond what the EPA has approved — but the ruling does not directly address design defect, negligence beyond labeling, or breach of warranty theories, which may remain viable for non-settling plaintiffs.
The Statute of Limitations: How Long You Have to File a Roundup Cancer Claim
This is one of the most common questions we hear, and the answer depends on two things: what state you live in, and when you discovered (or should have discovered) that your non-Hodgkin lymphoma was caused by glyphosate exposure.
The discovery rule. In toxic tort cases, the statute of limitations does not necessarily start running on the day you were exposed to Roundup. In most states, the clock starts when you discovered — or by reasonable diligence should have discovered — both your injury (the NHL diagnosis) and its cause (the connection to glyphosate exposure). This is called the discovery rule, and it is the reason many people whose exposure happened years or decades ago can still file claims today. A person diagnosed with NHL in 2023 who only learned in 2024 that glyphosate may have caused their disease may have a longer window than they think.
State-by-state variation. The personal injury statute of limitations varies by state — commonly two, three, or five years, depending on the jurisdiction. Missouri, where this settlement is pending, has a general personal injury limitation period of five years. But because this is a national mass tort, your individual claim’s deadline is governed by the law of the state where you live or where your exposure occurred. You should not assume you have “plenty of time” based on what you heard about someone else’s state — the deadline that controls is the one in your jurisdiction, and it is a hard bar that can extinguish your claim entirely if missed.
Tolling during the class action. If you are a member of the settlement class, the statute of limitations on your individual claim may be tolled (paused) while the class action is pending. This is a complex legal principle, and whether tolling applies to your specific situation depends on the specifics of the class certification and the jurisdiction. The practical implication: if the settlement is not approved at the August 19 hearing, or if it is modified, class members may have a window to file individual claims even if the raw SOL has passed — but this is not guaranteed and should not be relied upon without consulting an attorney in your state.
The outer limit — statute of repose. Some states have a statute of repose — an outer deadline that can cut off a claim even before the discovery rule would apply. If your state has a repose statute, it could bar your claim regardless of when you discovered the connection between Roundup and your cancer. This is a real trap, and it is why waiting to call a lawyer is the most dangerous thing a potential claimant can do.
The Objectors and the Removal Fight: Why the Procedural Posture Matters to You
The objectors — attorneys representing several individuals diagnosed with NHL who oppose the settlement — attempted to remove the case to federal court on May 22, seeking transfer to the federal Roundup MDL before Judge Vince Chhabria in the Northern District of California. Judge Chhabria has raised “grave concerns” about whether the settlement can legally bind people who may develop cancer in the future — people who have been exposed to Roundup but have not yet been diagnosed with NHL.
U.S. District Judge Henry Autrey ruled June 17 that the opponents lacked authority to move the case to federal court, sending it back to St. Louis state court. The objectors have appealed that ruling. Bayer’s subsidiary Monsanto asked Judge Boyer to postpone the hearing to address objections and opt-out disputes.
Why does this matter to you? Because the objectors are raising a constitutional question that affects every person in the settlement class and every person who might develop NHL in the future: Can a class action settlement constitutionally bind someone who does not yet know they are injured? Due process generally requires that class members have adequate notice and a meaningful opportunity to opt out before being bound. For people who have been exposed to Roundup but have not yet been diagnosed with cancer, they cannot meaningfully opt out of a settlement because they do not yet know they have a claim. Judge Chhabria’s “grave concerns” reflect this constitutional tension — and if the settlement is approved despite those concerns, it could be challenged on appeal on due process grounds.
The new briefing schedule set by Judge Boyer: all parties must file their motion for final approval and responses to objections by July 15. Objectors who filed timely objections in either state or federal court must file replies by July 29. The fairness hearing is August 19.
What to Do Right Now: The Evidence-Preservation and Decision Roadmap
Whether you are in the settlement class, whether you opted out, or whether you have been exposed but not yet diagnosed, here is what you should be doing right now:
If you are in the settlement class (you did not opt out by June 4):
– Gather and organize every document that establishes your Roundup exposure history: purchase receipts, product containers, photographs of Roundup use, employment records for agricultural/landscaping/groundskeeping work, and witness statements about the frequency and duration of your use.
– Obtain complete copies of your medical records: NHL diagnosis, pathology reports confirming subtype and stage, treatment history, oncologist records, and prognosis documentation.
– Monitor the August 19 fairness hearing. If the settlement is approved, you will receive an allocation according to the settlement matrix. If it is not approved, or if it is modified, you may have new options.
– Understand the net value of your settlement allocation after attorney fees and costs, and compare it honestly against the value of an individual case post-SCOTUS.
If you opted out by June 4:
– You retained your right to pursue an individual lawsuit. Your case will need to be built on the surviving legal theories — design defect, negligence beyond labeling, and breach of warranty — because the failure-to-warn theory is now preempted.
– Your exposure documentation and medical records are even more critical, because an individual case requires you to prove specific causation without the leverage of the settlement matrix.
– The statute of limitations on your individual claim is governed by your state’s law and the discovery rule — do not assume you have unlimited time.
If you have been exposed to Roundup but have not yet been diagnosed with NHL:
– The settlement’s ability to bind you is constitutionally uncertain. You may not be bound by a settlement you did not know you had a stake in.
– Preserve your exposure documentation now — receipts, containers, employment records, photographs. If you are diagnosed in the future, this evidence will be the foundation of your case, and it is the evidence that disappears fastest.
– Monitor the August 19 hearing and any appeals. If the settlement is approved and it purports to bind future claimants, there will be legal challenges to that provision.
For everyone:
– Do not sign anything without understanding what it means. If you receive a settlement allocation notice, do not accept it without understanding the net value after fees and the alternative of pursuing an individual case.
– Do not post about your case on social media. Defense counsel monitor social media, and a post about your health, your activities, or your state of mind can be used against you.
– Get your pathology report. The specific NHL subtype and stage are the foundation of both your settlement tier and your individual case value. If you do not have a copy, request it from your oncologist’s office.
Frequently Asked Questions
What does the Roundup settlement delay mean for my claim?
The delay means Judge Boyer postponed the final fairness hearing from July 9 to August 19 to allow more time to brief objections and account for the procedural disruption caused by the temporary removal to federal court. It does not kill the settlement, and it does not kill your rights. If you are in the settlement class, your claim remains pending. If the settlement is approved on August 19, you will receive an allocation according to the matrix. If it is not approved, or if it is modified, the case continues. The delay is procedural, not substantive — but it does give you more time to understand your options.
Can I still sue Monsanto individually if I didn’t opt out?
If you did not opt out by the June 4 deadline, you are currently within the settlement class, and the settlement — if approved — would bind your claim. You generally cannot pursue an individual lawsuit while remaining in the class. However, if the settlement is not approved at the August 19 hearing, or if it is significantly modified, the opt-out landscape could change. If you are uncertain about your status, the most important thing you can do is confirm whether your opt-out was timely filed — and if it was not, understand what your rights are within the settlement class.
What does the Supreme Court FIFRA ruling mean for Roundup lawsuits?
The Supreme Court ruled 7-2 that FIFRA — the federal pesticide law — preempts state-law failure-to-warn claims seeking cancer warnings on Roundup’s label. This means the primary legal theory that drove early Roundup verdicts — that Monsanto should have warned about cancer on the label — is now largely foreclosed for future state-law claims. However, the ruling specifically targets label-based failure-to-warn claims. It does not directly address design defect claims, negligence claims beyond labeling (such as failure to conduct adequate studies or manipulation of scientific literature), or breach of warranty claims. Those surviving theories are where the next chapter of Roundup litigation will be fought, and their viability is still being tested in courts across the country.
How much will I receive from the $7.25 billion Roundup settlement?
The $7.25 billion fund, spread across approximately 67,000 claimants, implies per-claimant allocations ranging from approximately $50,000 to $500,000+ depending on the tiering matrix — which considers diagnosis severity, exposure duration, age at exposure, and other factors. After attorney fees (typically 25-40% in mass tort cases) and litigation costs, a lower-tier claimant could receive a net payment below $50,000, while a higher-tier claimant could receive $200,000 to $350,000 or more. These are estimates, not guarantees. The actual allocation depends on the settlement matrix and the claims administrator’s determination. No one should tell you a specific dollar amount without reviewing your medical records and exposure history and applying them to the matrix.
Can the settlement bind people who get cancer in the future?
This is one of the most contested questions in the entire proceeding. Judge Vince Chhabria, the federal judge overseeing the Roundup MDL, has raised “grave concerns” about whether a class action settlement can constitutionally bind people who have been exposed to Roundup but have not yet been diagnosed with cancer. Due process generally requires that class members have adequate notice and a meaningful opportunity to opt out before being bound. People who do not yet know they are injured cannot meaningfully opt out of a settlement they do not know applies to them. If the settlement purports to bind future claimants and is approved despite those concerns, it will likely face legal challenges on due process grounds. If you have been exposed to Roundup but have not been diagnosed with NHL, you should not assume this settlement resolves your rights — and you should preserve your exposure documentation now.
What legal theories survive after the Supreme Court preemption ruling?
Three primary theories may survive: (1) design defect — the theory that Roundup was unreasonably dangerous in its design or formulation, or that a safer alternative was feasible; (2) negligence beyond labeling — claims that Monsanto failed to conduct adequate long-term carcinogenicity studies, manipulated scientific literature, ghostwrote studies, or failed in post-market surveillance; and (3) breach of implied warranty — the theory that Roundup was not fit for its ordinary purpose. Each of these faces challenges: they are less tested in the glyphosate context, and the defense will argue that any theory which would effectively require a different label is preempted just like a direct failure-to-warn claim. The viability of these theories will vary by jurisdiction and will be litigated case by case.
I used Roundup and was diagnosed with NHL — how long do I have to file?
The statute of limitations varies by state — commonly two, three, or five years, depending on your jurisdiction. In most states, the discovery rule applies, meaning the clock starts when you discovered (or by reasonable diligence should have discovered) both your injury and its cause. A person diagnosed with NHL who only recently learned about the Roundup-cancer connection may have a longer window than they think. However, some states have a statute of repose — an outer deadline that can bar a claim regardless of discovery. You should not assume you have plenty of time based on another state’s rules. The deadline that controls is the one in your state, and it is a hard bar that can extinguish your claim entirely if missed. The safest move is to have the deadline checked by an attorney in your jurisdiction — today, not next month.
What evidence do I need to preserve for a Roundup cancer claim?
Five categories: (1) medical records — your NHL diagnosis, pathology reports, treatment history, oncologist records; (2) exposure history — Roundup purchase receipts, product containers with lot numbers, employment records for agricultural/landscaping/groundskeeping work, witness statements about frequency and duration of use; (3) internal corporate documents — largely secured through prior MDL discovery, but your attorney should confirm what is available; (4) the regulatory and scientific record — IARC monograph, EPA filings, epidemiological studies; (5) expert witness reports and Daubert rulings from the MDL. The most urgent category is your personal exposure documentation — receipts degrade, containers are discarded, memories fade, and employment records are destroyed on standard retention schedules. If you have not already gathered this evidence, do it now.
Should I join the settlement or pursue an individual lawsuit?
This is a strategic decision that depends on the specific facts of your case: your NHL subtype and stage, your documented exposure history, the strength of your causation evidence, the venue where an individual case would be filed, and the surviving legal theories available post-SCOTUS. The settlement offers certainty — a known allocation within a known fund — but may not adequately compensate someone whose individual case could be worth more. An individual lawsuit offers the potential for a higher recovery, but carries the risk of the preemption ruling, the uncertainty of surviving legal theories, and the time and stress of litigation. This decision should be made with full information about both options, and it should be made with an attorney who understands the post-SCOTUS landscape and can evaluate your specific case honestly.
What if I was exposed to Roundup but haven’t been diagnosed with cancer yet?
Your situation is the most legally uncertain. The settlement’s ability to bind you — a future claimant — is constitutionally questionable. You may not be bound by a settlement you did not know you had a stake in. But you also cannot file a lawsuit yet, because you have not been injured in the legal sense — a cancer diagnosis is the injury that triggers the claim. What you can do is preserve your exposure documentation now, so that if you are diagnosed in the future, the evidence of your Roundup use is still available. The exposure evidence is the fastest-dying category — receipts, containers, and memories all degrade. Preserve them now, in a file, with dates and photographs. And monitor the August 19 hearing and any appeals, because the resolution of the future-claimant question will directly affect your rights.
Who We Are and How We Help
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes toxic tort and product liability cases for people whose lives were overturned by a product they were told was safe. We are not counsel in the Roundup MDL or in the St. Louis settlement proceeding — this page is legal information and education, not legal advice, and nothing here creates an attorney-client relationship. But we handle these cases, and we know the post-SCOTUS landscape that is now reshaping every Roundup claim in the country.
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He is admitted to the U.S. District Court for the Southern District of Texas. He was a journalist before he was a lawyer — which means he reads the documents the way a reporter reads them, looking for the sentence the company did not want you to find. He is the managing partner of the firm, licensed in Texas since November 1998, and a member of the Texas Trial Lawyers Association and the Houston Bar Association.
Lupe Peña is a former insurance-defense attorney. He spent years inside a national defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He knows how the other side values claims, how they pick their experts, and how they build their defenses — because he used to build them. Now he sits on your side of the table. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. If your family communicates in Spanish, your case will be handled in your language — not through a translation app.
We work on contingency. That means we do not get paid unless we win your case. The fee is 33.33% before trial and 40% if the case goes to trial. Your first consultation is free, and it is confidential. Call us at 1-888-ATTY-911 — 1-888-288-9911 — and you will reach a live person, 24 hours a day, 7 days a week. Not an answering service. A person.
Hablamos Español.
The Bottom Line
The Roundup litigation landscape changed on June 25, 2026, when the Supreme Court ruled that FIFRA preempts state-law failure-to-warn claims. The settlement hearing was delayed from July 9 to August 19. These two events together mean that every person with a Roundup NHL claim — whether in the settlement class, whether opted out, or whether exposed but not yet diagnosed — needs to understand the new terrain and make decisions with full information.
The failure-to-warn theory is largely foreclosed. Design defect, negligence beyond labeling, and breach of warranty may survive. The settlement may or may not be approved on August 19. The settlement’s ability to bind future claimants is constitutionally uncertain. Your personal exposure documentation is dying every day you wait. The statute of limitations in your state is a hard bar that can extinguish your claim if you wait too long.
The most important thing you can do right now is not wait. Gather your evidence. Get your medical records. Understand your options. And have a conversation with a lawyer who can tell you honestly whether the settlement or an individual case is the right path for your specific facts.
Past results depend on the facts of each case and do not guarantee future outcomes.
Call 1-888-ATTY-911. The consultation is free. The call is confidential. And the person who answers is not a recording — they are part of a team that has been doing this for over 24 years. We will tell you the truth about your case, even if the truth is hard. Especially then.
